Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Go online to PeerView.com/ZUH860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Nurses play an essential role in caring for patients with
diffuse large b-cell lymphoma (DLBCL); learn more about the core
elements of nursing practice in this PeerView video activity,
featuring two leading oncology nurses who will focus on novel
antibody and CAR-T cell therapies for the management of R/R DLBCL.
Using a case-based format, the panelists will detail how antibodies
and CAR-T therapy are now a part of the treatment toolkit and
provide guidance on important considerations including: therapeutic
sequencing, safety concerns, and counseling patients on appropriate
dosing, treatment schedules, and premedication recommendations.
Upon completion of this activity, participants should be better
able to: Cite current clinical evidence supporting the integration
of novel antibody and CAR-T cell therapies for the management of
diffuse large B-cell lymphoma (DLBCL); Educate patients on safety,
dosing, and treatment expectations associated with novel CD19,
CD79, and CD3/CD20 targeting antibodies in the DLBCL setting;
Counsel patients on the therapeutic role of cellular therapy in
DLBCL, efficacy expectations, unique pre-therapy requirements, and
adverse events such as CRS and neurotoxicity; and Manage practical
considerations with novel antibodies and CAR-T therapy in DLBCL,
including coordination of clinical visit or referral to specialized
care, dosing considerations, and management of unique adverse
events.